P02.03 Automated cell type specific PD-L1 quantification by artificial intelligence using high throughput bleach & stain 15-marker multiplex fluorescence immunohistochemistry in human cancers
نویسندگان
چکیده
Background The quantification of PD-L1 (programmed cell death ligand 1) has been used to predict patient’s survival, characterize the tumor immune microenvironment, and response checkpoint therapies. However, a framework assess status with high interobserver reproducibility on cells different types yet be established. Materials Methods To study impact expression microenvironment patient outcome, for fully automated was established validated. Automated facilitated by incorporating three deep learning steps analysis more than 80 neoplasms from 10’000 specimens using bleach & stain 15-marker multiplex fluorescence immunohistochemistry panel (i.e., PD-L1, PD-1, CTLA-4, panCK, CD68, CD163, CD11c, iNOS, CD3, CD8, CD4, FOXP3, CD20, Ki67, CD31). Clinicopathological parameter were available 30 entities overall survival data 1517 breast cancer specimens. Results Comparing deep-learning based conventional brightfield revealed concordance in (p<0.0001) as well an accuracy ranging 90% 95.2%. Across all entities, level significantly higher distinct macrophage/dendritic (DC) subsets (identified iNOS; p<000.1) macrophages/DCs located Stroma compared intratumoral macrophages/DC subsets. highly variable driven phenotypes identified intensity both cells, distance between non-exhausted T-cell (i.e. PD-1 CTLA-4 CD3 + CD8 cytotoxic T-cells, CD4 T-helper FOXP3 regulatory T-cells) macrophage/(DC) subtypes. In cancer, showed predictive performance area under receiver operating curves (AUC) 0.72 percentage (AUC: 0.54). positive negative cancers close spatial relationship T- (CD3 ± ) Macrophage/DC (CD68 CD163 CD11c iNOS) found prognostic relevant (p<0.0001). Conclusions conclusion, immunofluorescence assessment provides cutoff-free/continuous which are superior relevance. combined PD-L1/PD-1 20 subtypes phenotypes. Disclosure Information N.C. Blessin: None. E. Bady: T. Mandelkow: C. Yang: J. Raedler: R. Simon: Fraune: M. Lennartz: S. Minner: Burandt: D. Höflmayer: G. Sauter: S.A. Weidemann:
منابع مشابه
Stain Unmixing in Brightfield Multiplex Immunohistochemistry Images
Multiplex immunohistochemistry (IHC) staining is a newly emerging technique for the detection of multiple biomarkers within a single tissue section and has become more popular due to its significant efficiency and the rich diagnostic information it contains. Therefore, to accurately unmix the IHC image and differentiate all the stains is of tremendous clinical importance since it is the initial...
متن کاملDevelopment of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer
Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune checkpoint inhibitor antibody, developed by Bristol-Myers Squibb Inc., has activity across non-small cell lung cancer (NSCLC) histologies and is Food and Drug Administration approved for treatment of metastatic squamous NSCLC with progression on or after platinum-based chemotherapy. PD-L1 has been investigated as a potential biomark...
متن کاملUse of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
BACKGROUND For non-small cell lung cancer (NSCLC), treatment with pembrolizumab is limited to patients with tumours expressing PD-L1 assessed by immunohistochemistry (IHC) using the PD-L1 IHC 22C3 pharmDx (Dako, Inc.) companion diagnostic test, on the Dako Autostainer Link 48 (ASL48) platform. Optimised protocols are urgently needed for use of the 22C3 antibody concentrate to test PD-L1 express...
متن کاملCell-specific PD-L1 expression in DLBCL.
In this issue of Blood, a new study by Kiyasu et al used a double-staining technique to identify cell-specific programmed cell death ligand 1 (PD-L1) expression in 1253 diffuse large B-cell lymphoma (DLBCL) samples and analyzed the findings together with programmed death-1 (PD-1) expression in tumorinfiltrating lymphocytes (TILs) and clinical outcomes, providing new insights into the role of th...
متن کاملCorrection: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms
[This corrects the article DOI: 10.1371/journal.pone.0183023.].
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal for ImmunoTherapy of Cancer
سال: 2021
ISSN: ['2051-1426']
DOI: https://doi.org/10.1136/jitc-2021-itoc8.15